Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients
Abstract Tyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate the utility of plasma cell-free DNA (cfDNA) as a...
Enregistré dans:
Auteurs principaux: | , , , , , , , , , , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b2343cf2b10446a4ab9c404bea005c66 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|